Europhyto Technology Serving Agriculture S.R.L. - hasil pencarian

Uni Eropa - Jerman - EMA (European Medicines Agency)

adakveo

novartis europharm limited - crizanlizumab - anämie, sichelzellen - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Uni Eropa - Jerman - EMA (European Medicines Agency)

leqvio

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipidmodifizierende mittel - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Uni Eropa - Jerman - EMA (European Medicines Agency)

tabrecta

novartis europharm limited - capmatinib dihydrochloride monohydrate - karzinom, nicht kleinzellige lunge - antineoplastische mittel - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Uni Eropa - Jerman - EMA (European Medicines Agency)

locametz

novartis europharm limited - gozetotide - radionuklid-bildgebung - diagnostische radiopharmaka - dieses arzneimittel ist nur für diagnostische zwecke bestimmt. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Uni Eropa - Jerman - EMA (European Medicines Agency)

pluvicto

novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - prostatahyperplasie neubildungen, kastration-resistentem - therapeutische radiopharmazeutika - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.